CoChat

Presenilin-1 280Glu→Ala Mutation Alters C-Terminal APP Processing Yielding Longer Aβ Peptides: Implications for Alzheimer’s Disease

Open access
Van Vickle, Gregory D., Esh, Chera L., Kokjohn, Tyler A., Patton, R. Lyle, Kalback, Walter M., Luehrs, Dean C., Beach, Thomas G., Newel, Amanda J., Lopera, Francisco, Ghetti, Bernardino, Vidal, Ruben, Castaño, Eduardo M., Roher, Alex E. · 2008 · Molecular Medicine
Cited by 25

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Presenilin (PS) mutations enhance the production of the Abeta42 peptide that is derived from the amyloid precursor protein (APP). The pathway(s) by which the Abeta42 species is preferentially produced has not been elucidated, nor is the mechanism by which PS mutations produce early-onset dementia established. Using a combination of histological, immunohistochemical, biochemical, and mass spectrometric methods, we examined the structural and morphological nature of the amyloid species produced in a patient expressing the PS1 280Glu-->Ala familial Alzheimer's disease mutation. Abundant diffuse plaques were observed that exhibited a staining pattern and morphology distinct from previously described PS cases, as well as discreet amyloid plaques within the white matter. In addition to finding increased amounts of CT99 and Abeta42 peptides, our investigation revealed the presence of a complex array of Abeta peptides substantially longer than 42/43 amino acid residue species. The increased hydrophobic nature of longer Abeta species retained within the membrane walls could impact the structure and function of plasma membrane and organelles. These C-terminally longer peptides may, through steric effects, dampen the rate of turnover by critical amyloid degrading enzymes such as neprilysin and insulin degrading enzyme. A complete understanding of the deleterious side effects of membrane bound Abeta as a consequence of gamma-secretase alterations is needed to understand Alzheimer's disease pathophysiology and will aid in the design of therapeutic interventions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2119/2007-00094.vanvickle

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 25

Metadata

Authors
Van Vickle, G. D., Esh, C. L., Kokjohn, T. A., Patton, R. L., Kalback, W. M., Luehrs, D. C., Beach, T. G., Newel, A. J., Lopera, F., Ghetti, B., Vidal, R., Castaño, E. M., & Roher, A. E.
Venue
Molecular Medicine
Published
2008-03
Volume
14
Issue
3-4
Pages
184-194
ISSN
  • 1076-1551 (ISSN-L)
  • 1528-3658
OpenAlex
W2408943199
Cited by
25
References
12
FWCI
1.41
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Presenilin-1 280Glu→Ala Mutation Alters C-Terminal APP Processing Yielding Longer Aβ Peptides: Implications for Alzheimer’s Disease. https://app.cochat.ai/papers/10.2119/2007-00094.vanvickle
The paper
Van Vickle, G. D., Esh, C. L., Kokjohn, T. A., Patton, R. L., Kalback, W. M., Luehrs, D. C., Beach, T. G., Newel, A. J., Lopera, F., Ghetti, B., Vidal, R., Castaño, E. M., & Roher, A. E. (2008). Presenilin-1 280Glu→Ala Mutation Alters C-Terminal APP Processing Yielding Longer Aβ Peptides: Implications for Alzheimer’s Disease. Molecular Medicine. https://doi.org/10.2119/2007-00094.vanvickle

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.